@article {680426,
	title = {Infliximab after Boston Keratoprosthesis in Stevens-Johnson Syndrome: An Update.},
	journal = {Ocul Immunol Inflamm},
	year = {2016},
	month = {2016 Mar 25},
	pages = {1-5},
	abstract = {PURPOSE: To report our experience using intravenous infliximab for the treatment of tissue melt after Boston keratoprosthesis (B-KPro) types I and II in patients with autoimmune disease. METHODS: Case series. RESULTS: We identified four patients who were treated with intravenous infliximab in the context of tissue melt after B-KPro. Stevens-Johnson syndrome-associated corneal blindness was the primary surgical indication for B-KPro implantation in all patients. Two patients received a B-KPro type I and two patients received a B-KPro type II. The patients received intravenous infliximab for skin retraction around B-KPro type II, melting of the carrier graft or leak. Treatment resulted in a dramatic decrease in inflammation and, in some cases, arrest of the melting process. Cost and patient adherence were limiting factors to pursuing infliximab therapy. In addition, one patient developed infusion reactions. CONCLUSIONS: Intravenous infliximab may be considered as globe- and sight-saving therapy for tissue melt after B-KPro.},
	issn = {1744-5078},
	doi = {10.3109/09273948.2016.1145237},
	author = {Robert, Marie-Claude and {\v C}rnej, Alja and Shen, Lucy Q and Papaliodis, George N and Dana, Reza and Foster, C Stephen and Chodosh, James and Dohlman, Claes H}
}
